TC BioPharm (Holdings) (TC BioPharm (Holdings)) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. TC BioPharm (Holdings)'s annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. TC BioPharm (Holdings)'s average Total Assets over the quarter that ended in Mar. 2024 was $10.27 Mil. Therefore, TC BioPharm (Holdings)'s annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

TC BioPharm (Holdings) Gross-Profit-to-Asset % Historical Data

The historical data trend for TC BioPharm (Holdings)'s Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Gross-Profit-to-Asset % Chart

TC BioPharm (Holdings) Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

33.79

23.07

25.76

38.35

TC BioPharm (Holdings) Quarterly Data
	Dec19	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of TC BioPharm (Holdings)'s Gross-Profit-to-Asset %

For the Biotechnology subindustry, TC BioPharm (Holdings)'s Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TC BioPharm (Holdings)'s Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TC BioPharm (Holdings)'s Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where TC BioPharm (Holdings)'s Gross-Profit-to-Asset % falls into.

TC BioPharm (Holdings) Gross-Profit-to-Asset % Calculation

TC BioPharm (Holdings)'s annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (13.754	+	11.306)	/ 2 )
	=	0	/	12.53
	=	0.00 %

TC BioPharm (Holdings)'s annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (11.306	+	9.23)	/ 2 )
	=	0	/	10.268
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

TC BioPharm (Holdings) Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

T0U:Germany

Address

Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR

Website

https://www.tcbiopharm.com

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

Executives

Renaissance Capital Partners Ltd	10 percent owner	42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD